COMMUNIQUÉS West-GlobeNewswire

EDAP Announces Filing of New 510(k) Application for Focal One® Device

11/09/2017 - 13:30

510(k) Includes New Clinical Data to Support EDAP's File LYON, France, September 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a new 510(k [...]

Genedrive® HCV ID Kit received CE-IVD Certification

11/09/2017 - 13:30

11 September 2017 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit received CE-IVD Certification Hepatitis C assay provides decentralised molecular testing to support the identification of patients [...]

Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market

11/09/2017 - 13:00

SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into [...]

ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting

11/09/2017 - 13:00

Phase 1 clinical trial results in healthy subjects support cardiac safety of OBE022 Geneva, Switzerland and Boston, MA - 11 September, 2017 - ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the [...]

Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

11/09/2017 - 13:00

Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Median [...]

Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI

11/09/2017 - 13:00

Summit Therapeutics plc ('Summit Therapeutics', Summit', or the 'Company') SUMMIT AWARDED BARDA CONTRACT WORTH UP TO $62 MILLION TO SUPPORT THE DEVELOPMENT OF RIDINILAZOLE FOR THE TREATMENT OF C. DIFFICILE INFECTION [...]

Shire plc : Elections for the interim dividend in respect of the six months to June 30, 2017

11/09/2017 - 13:00

Elections for the interim dividend in respect of the six months to June 30, 2017 September 11, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announced on August 3, 2017, an interim dividend of 5.09 US cents [...]

Medtronic Announces Voluntary Recall of Diabetes Infusion Sets

11/09/2017 - 12:45

DUBLIN - September 11, 2017 - Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin [...]

Novo Nordisk A/S - Share repurchase programme

11/09/2017 - 12:26

Bagsværd, Denmark, 11 September 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Symphogen A/S: Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

11/09/2017 - 09:45

Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress Data show clinically meaningful improvement in overall survival in a [...]

Virbac : Déclaration d'actions et de droits de vote au 31 Août 2017

11/09/2017 - 09:29

DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]

Virbac : Declaration of the number of shares and voting rights as of August 2017, 31.

11/09/2017 - 09:29

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

Virbac : Déclaration d'actions et de droits de vote au 31 Juillet 2017

11/09/2017 - 09:20

DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]

Virbac : Declaration of the number of shares and voting rights as of July 2017, 31.

11/09/2017 - 09:20

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress

11/09/2017 - 09:15

MADRID, September 11, 2017 - This morning at the European Society for Medical Oncology (ESMO) 2017 Congress, Dr. James Gulley, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

11/09/2017 - 09:00

FIT Biotech Oy Company release September 11, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

Solon Eiendom ASA : Primary insider notification

11/09/2017 - 08:30

(Oslo, Norway, 08 September 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 133,553 shares in Solon Eiendom ASA at a price of NOK 17.5373 per [...]

Xbrane confirms order of Spherotide to value of SEK 8.5 million and more than 10,000 doses sold

11/09/2017 - 08:00

Press release 2017-09-11 Xbrane has confirmed an additional order of Spherotide from Pooyesh Darou, its partner in the Middle East, to a value of SEK 8.5 million to be delivered in Q4 2017. With this delivery Xbrane [...]

Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups.

11/09/2017 - 08:00

Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu have made an initial evaluation of the top line data of the Phase II "Randomized, double blind, parallel-group, dose escalation placebo- [...]